User:Blent/Seminar 07 fall: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
|||
(44 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Title== | ==Title== | ||
* Toward Personalized Medicine in BMI-based Methodology: A case study of [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] and challenges in the future | * Toward Personalized Medicine in BMI-based Methodology: A case study of [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] and challenges in the future | ||
==Outlines (Sep | |||
* case study | ==Outlines (Sep 30, 2007)== | ||
=== What is personalized medicine === | |||
* personalized biomedical data collection and analysis | |||
* | ** easy-to-use personalized diagnosis kit | ||
* | * personalized biomedical date-driven medicine usage | ||
** which medicine should one take? (decision of medicine) | |||
** [http:// | ** how much medicine should one take? (dosage of medicine) | ||
* | * references | ||
* | ** [http://www.personalizedmedicinecoalition.org/ personalized medicine coalition] | ||
** | ** [http://www.genomenewsnetwork.org/articles/2004/10/28/matchingpatients.php Personalized Medicine in Cancer: Matching Patients and Drugs (Genome News Network, Oct 28th, 2004)] | ||
*** [http://en.wikipedia.org/wiki/Gefitinib Gefitinib, a cancer drug] | |||
** [http://www.boston.com/news/globe/editorial_opinion/oped/articles/2005/07/17/personalized_medicine/ Personalized medicine: A new approach to staying well (Boston Globe News, July 17th, 2005)] | |||
** [http://www.fda.gov/fdac/features/2005/605_genomics.html Genomics and Personalized Medicine (FDA Consumer magazine, Nov-Dec 2005 issue)] | |||
*** [http://www.fda.gov/cder/genomics/default.htm Genomics at FDA] | |||
=== case study: CBZ-SJS === | |||
* [http://www.nature.com/nature/journal/v428/n6982/full/428486a.html Medical genetics: a marker for Stevens-Johnson syndrome, 2004 April Nature] | |||
** HLA-B 1520 is an universal marker for Han Chinese in Taiwan | |||
** [http://brc.se.fju.edu.tw/protein/analysis/ms.htm MS蛋白質序列分析] | |||
** [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=12164776&dopt=AbstractPlus MALDI-TOF mass spectrometry-based SNP genotyping, 2002 Pharmacogenomics] | |||
** [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11295828 High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise, 2001 Hum Mutat.] | |||
* [http://www.nature.com/tpj/journal/v6/n4/full/6500356a.html A marker for Stevens-Johnson syndrome ...: ethnicity matters, 2006 The Pharmacogenomics Journal] | |||
** HLA-B 1502 may '''NOT''' be an universal marker for CBZ-SJS | |||
* [http://www.nature.com/nrd/journal/v4/n1/full/nrd1605.html Genetic aspects of immune-mediated adverse drug effects, 2005 Nature] | |||
* [http://www.nature.com/jid/journal/v114/n1/full/5600617a.html Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome, 2000 Journal of Investigative Dermatology] | |||
* [http://sa.ylib.com/news/newsshow.asp?FDocNo=438&CL=28 嚴重藥物過敏,可以預防 (科學人 2004 May)] | |||
* [http://explore.pts.org.tw/p2.htm 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏] | |||
* [http://tw.myblog.yahoo.com/a_jun35/article?mid=1163&prev=1224&next=1161&l=f&fid=22 基因型鑑定 預防藥物過敏邁向個人化醫療 (中廣新聞網 3/8, 2007)] | |||
* [http://drug.doh.gov.tw/bulletin_cnt.php?PHPSESSID=bg6ksuvuq317fmk4runq4232b6&Pact=bulletin&id=160 我國個人化醫療跨出一大步,讓藥害救濟由事後救濟邁向事前預防 (行政院衛生署藥物資訊網 9/17, 2007)] | |||
* [http://www.libertytimes.com.tw/2007/new/sep/18/today-life7.htm 預防抗癲癇藥害 明年起先測基因 - 首見研究成果當警語 (自由時報生活新聞 9/18, 2007)] | |||
* [http://www.epochtimes.com/b5/7/9/18/n1837459.htm 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)] | |||
* [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] is an long half-live drug | |||
=== case study: Warfarin (抗凝血劑) and dosage estimation === | |||
* [http://www.aafp.org/afp/990201ap/635.html Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician] | |||
* [http://genome.wellcome.ac.uk/doc_WTD020935.html Genetic variation (VKORC1) alters response to warfarin, 2/6/05. By NIH/National Institute of General Medical Sciences] | |||
* [http://www.clinchem.org/cgi/content/full/53/9/1721 Genetic Factors for Warfarin Dose Prediction, 2007 Clinical Chemistry] | |||
=== case study: Diabetes and Diagnosis === | |||
=== BioBank and Biomarkers discovery === | |||
=== case study: The First race-specific drug '''[http://www.bidil.com/ BiDil]'''=== | |||
* [http://www.liverx.org/2007/09/05/藥瓶裡的種族問題/ 活力藥師網番外篇-藥瓶裡的種族問題] | |||
* [http://www.sciam.com/article.cfm?chanID=sa006&colID=1&articleID=B0FEC94D-E7F2-99DF-3CD8F25918B63A39 Race in a Bottle, Jonathan Kahn. (Sci Am 2007 Aug)] | |||
* 藥瓶裡的種族問題 科學人 2007 Sep | |||
* author: [http://www.hamline.edu/law/facadmin/jonathon_kahn.html Jonathan Kahn] | |||
* [http://findarticles.com/p/articles/mi_m1365/is_4_36/ai_n15890897 Are race-specific drugs unethical? With BiDil on the market, experts weigh the moral implications, Nov 2005] | |||
* [http://en.wikipedia.org/wiki/Isosorbide_dinitrate/hydralazine BiDil: Isosorbide dinitrate and hydralazine] | |||
** [http://www.pharmacychecker.com/Pricing.asp?DrugName=Hydralazine&DrugId=18834&DrugStrengthId=30707 Hydralazine price] | |||
** [http://www.pharmacychecker.com/Pricing.asp?DrugName=Isosorbide+Dinitrate&DrugId=18878&DrugStrengthId=30779 Isosorbide Dinitrate price] | |||
** [http://www.pharmacychecker.com/Pricing.asp?DrugName=Bidil&DrugId=62798&DrugStrengthId=115893 BiDil price] | |||
=== ELSI, Biobank and FDA guide lines === | |||
=== Movies === | |||
* [http://movie.starblvd.net/cgi-bin/movie/euccns?/film/1997/Gattaca/Gattaca.html Gattaca: 千鈞一髮 1997] | |||
==Outlines (Sep 20, 2007) == | ==Outlines (Sep 20, 2007) == | ||
* BMI = BI + MI | * BMI = BI + MI | ||
Line 43: | Line 84: | ||
* [http://www.bioweb.com.tw/ 華文生技網] | * [http://www.bioweb.com.tw/ 華文生技網] | ||
* [http://140.119.115.32/sa/defaultx.asp 科學人知識庫] | * [http://140.119.115.32/sa/defaultx.asp 科學人知識庫] | ||
== | ==Notes== | ||
* [[User:Blent/Scientific_American|Scientific American]] | * [[User:Blent/Scientific_American|Scientific American]] | ||
* [[User:Blent/Biobank|Biobank]] | * [[User:Blent/Biobank|Biobank]] |
Latest revision as of 22:50, 1 October 2007
Title
- Toward Personalized Medicine in BMI-based Methodology: A case study of Carbamazepine and challenges in the future
Outlines (Sep 30, 2007)
What is personalized medicine
- personalized biomedical data collection and analysis
- easy-to-use personalized diagnosis kit
- personalized biomedical date-driven medicine usage
- which medicine should one take? (decision of medicine)
- how much medicine should one take? (dosage of medicine)
- references
- personalized medicine coalition
- Personalized Medicine in Cancer: Matching Patients and Drugs (Genome News Network, Oct 28th, 2004)
- Personalized medicine: A new approach to staying well (Boston Globe News, July 17th, 2005)
- Genomics and Personalized Medicine (FDA Consumer magazine, Nov-Dec 2005 issue)
case study: CBZ-SJS
- Medical genetics: a marker for Stevens-Johnson syndrome, 2004 April Nature
- HLA-B 1520 is an universal marker for Han Chinese in Taiwan
- MS蛋白質序列分析
- MALDI-TOF mass spectrometry-based SNP genotyping, 2002 Pharmacogenomics
- High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise, 2001 Hum Mutat.
- A marker for Stevens-Johnson syndrome ...: ethnicity matters, 2006 The Pharmacogenomics Journal
- HLA-B 1502 may NOT be an universal marker for CBZ-SJS
- Genetic aspects of immune-mediated adverse drug effects, 2005 Nature
- Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome, 2000 Journal of Investigative Dermatology
- 嚴重藥物過敏,可以預防 (科學人 2004 May)
- 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏
- 基因型鑑定 預防藥物過敏邁向個人化醫療 (中廣新聞網 3/8, 2007)
- 我國個人化醫療跨出一大步,讓藥害救濟由事後救濟邁向事前預防 (行政院衛生署藥物資訊網 9/17, 2007)
- 預防抗癲癇藥害 明年起先測基因 - 首見研究成果當警語 (自由時報生活新聞 9/18, 2007)
- 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)
- Carbamazepine is an long half-live drug
case study: Warfarin (抗凝血劑) and dosage estimation
- Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician
- Genetic variation (VKORC1) alters response to warfarin, 2/6/05. By NIH/National Institute of General Medical Sciences
- Genetic Factors for Warfarin Dose Prediction, 2007 Clinical Chemistry
case study: Diabetes and Diagnosis
BioBank and Biomarkers discovery
case study: The First race-specific drug BiDil
- 活力藥師網番外篇-藥瓶裡的種族問題
- Race in a Bottle, Jonathan Kahn. (Sci Am 2007 Aug)
- 藥瓶裡的種族問題 科學人 2007 Sep
- author: Jonathan Kahn
- Are race-specific drugs unethical? With BiDil on the market, experts weigh the moral implications, Nov 2005
- BiDil: Isosorbide dinitrate and hydralazine
ELSI, Biobank and FDA guide lines
Movies
Outlines (Sep 20, 2007)
- BMI = BI + MI
- what BMI can do
- Neuroinformatics (NI)
- Cancer research (CR)
- what BMI can do
- Personalized Medicine (PM)
- Motivation and case study
- Stevens-Johnson syndrome and HLA-B 1502
- Methodology
- MI
- BI
- Products
- Problems remained
- Motivation and case study
Background
- intersection between Bioinformatics and Medical Informatics
- total search results
- Bioinformatics and Medical Informatics: Collaborations on the Road to Genomic Medicine? 2003 JAMIA
- The Interactions Between Clinical Informatics and Bioinformatics, 2000 JAMIA
- Opportunities at the Intersection of Bioinformatics and Health Informatics, 2000 JAMIA
- Training the Next Generation of Informaticians: The Impact of "BISTI" and Bioinformatics—A Report from the American College of Medical Informatics, 2004 JAMIA
- Military Research Needs in Biomedical Informatics, 2000 JAMIA
- Synergies in Medical Informatics and Bioinformatics
Materials
- Scientific American (English)
- Scientific American (Taiwan)
- BioIT
- Genetic Engineering & biotechnology News
- 華文生技網
- 科學人知識庫